cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cara Therapeutics Inc
25 own
57 watching
Current Price
$4.72
$0.12
(2.61%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
19.09M
52-Week High
52-Week High
13.80000
52-Week Low
52-Week Low
2.71200
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
107.2671
iconMarket Capitalization19.09M
icon52-Week High13.80000
icon52-Week Low2.71200
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio107.2671
What does the Cara Therapeutics Inc do?
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Read More
How much money does Cara Therapeutics Inc make?
News & Events about Cara Therapeutics Inc.
Globe Newswire
1 year ago
STAMFORD, Conn., April 10, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.(Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive ...
Benzinga
1 year ago
read more...
Ticker Report
2years ago
Cara Therapeutics, Inc. (NASDAQ:CARA Get Rating) Director Martin Vogelbaum sold 10,800 shares of Cara Therapeutics stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $10.28, for a total value of $111,024.00. Following the transaction...
Globe Newswire
2years ago
Kapruvia (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy recently approved in Canada under the brand name KORSUVA Regulatory decisions in Australia and Singapore ...
Globe Newswire
2years ago
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patientsFirst launches in Europe expected in H2 2022 ST. GALLEN, Switzerland and STAMFORD, Conn., April 28, 2022 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (...
Frequently Asked Questions
Frequently Asked Questions
What is Cara Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Cara Therapeutics Inc shares?
plus_minus_icon
How can I buy Cara Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Cara Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cara Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Cara Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Cara Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cara Therapeutics Inc?
plus_minus_icon
What percentage is Cara Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cara Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4.72
$0.12
(2.61%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Kala Pharmaceuticals Inc
Kala Pharmaceuticals Inc
$7.69
$0.01 (0.13 %)
Bioxcel Therapeutics
Bioxcel Therapeutics
$0.36
$0.00 (1.01 %)
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$2.11
$-0.07 (-3.43 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$0.54
$0.00 (0.50 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Kala Pharmaceuticals Inc
Kala Pharmaceuticals Inc
$7.69
$0.01 (0.13 %)
Bioxcel Therapeutics
Bioxcel Therapeutics
$0.36
$0.00 (1.01 %)
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$2.11
$-0.07 (-3.43 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$0.54
$0.00 (0.50 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00